WO2021259244A1 - Petit arn en épingle à cheveux pour inhiber la réplication du virus sars-cov-2 et application d'un petit arn en épingle à cheveux - Google Patents

Petit arn en épingle à cheveux pour inhiber la réplication du virus sars-cov-2 et application d'un petit arn en épingle à cheveux Download PDF

Info

Publication number
WO2021259244A1
WO2021259244A1 PCT/CN2021/101493 CN2021101493W WO2021259244A1 WO 2021259244 A1 WO2021259244 A1 WO 2021259244A1 CN 2021101493 W CN2021101493 W CN 2021101493W WO 2021259244 A1 WO2021259244 A1 WO 2021259244A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
shrna
virus
sequence shown
cov
Prior art date
Application number
PCT/CN2021/101493
Other languages
English (en)
Chinese (zh)
Inventor
苏金
赵金存
杨鹏辉
孙静
苗凯
Original Assignee
深圳霁因生物医药转化研究院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳霁因生物医药转化研究院 filed Critical 深圳霁因生物医药转化研究院
Publication of WO2021259244A1 publication Critical patent/WO2021259244A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Definitions

  • the invention relates to a shRNA (short hairpin RNA), in particular to a shRNA for inhibiting SARS-COV-2 virus replication and its application.
  • shRNA short hairpin RNA
  • New Coronavirus Pneumonia (Corona Virus Disease 2019, COVID-19), referred to as "New Coronary Pneumonia”, is a global pandemic with the widest impact that humans have encountered in the past 100 years, posing a huge threat to global public health security. At present, there is no specific treatment or medicine for new coronary pneumonia. Disease control mainly relies on strict physical isolation to cut off the transmission route, which directly causes serious economic losses.
  • the following methods can be used for treatment: (1) Respiratory support, including oxygen therapy, high-flow nasal catheter oxygen therapy or non-invasive mechanical ventilation, invasive mechanical ventilation and rescue treatment; (2) Circulatory support, adequate On the basis of fluid resuscitation, improve microcirculation, use vasoactive drugs, and perform hemodynamic testing if necessary; (3) Renal failure and renal replacement therapy; (4) Recovered patients' plasma therapy; (5) Blood purification therapy, etc. .
  • the following methods can be used for treatment: bed rest, attention to maintaining a stable internal environment, and timely effective oxygen therapy measures based on oxygen saturation.
  • the drug treatments that can be tried include: interferon alpha, lopinavir/ritonavir, ribavirin, chloroquine phosphate and arbidol, ribavirin, etc.
  • the treatment course of trial drugs should not exceed 10 days. Relevant drugs should be stopped when untolerable side effects occur.
  • siRNA that inhibits SARS-CoV-2 virus replication, wherein the siRNA targets one of the E, M, and N genes of the SARS-CoV-2 virus and includes any one selected from the following combinations A pair of sequences:
  • Another aspect of the present invention provides a shRNA that inhibits SARS-CoV-2 virus replication, wherein the shRNA targets one of the E, M, and N genes of the SARS-CoV-2 virus and comprises a combination selected from Any pair of sequences:
  • Another aspect of the present invention provides a shRNA that inhibits SARS-CoV-2 virus replication, wherein the shRNA targets one of the E, M, and N genes of the SARS-CoV-2 virus and includes SEQ ID NO: 11 Any one of the sequences shown in -15.
  • Another aspect of the present invention provides a DNA encoding shRNA that inhibits SARS-CoV-2 virus replication, wherein the shRNA targets one of the E, M, and N genes of the SARS-CoV-2 virus, and the DNA comprises Any set of sequences selected from the following combinations:
  • the sense strand contains the sequence shown in SEQ ID NO: 16 and SEQ ID NO: 17, and the antisense strand contains the sequence shown in SEQ ID NO: 26 and SEQ ID NO: 27;
  • the sense strand includes the sequence shown in SEQ ID NO: 18 and SEQ ID NO: 19, and the antisense strand includes the sequence shown in SEQ ID NO: 28 and SEQ ID NO: 29;
  • the sense strand includes the sequence shown in SEQ ID NO: 20 and SEQ ID NO: 21, and the antisense strand includes the sequence shown in SEQ ID NO: 30 and SEQ ID NO: 31;
  • the sense strand contains the sequence shown in SEQ ID NO: 22 and SEQ ID NO: 23, and the antisense strand contains the sequence shown in SEQ ID NO: 32 and SEQ ID NO: 33;
  • the sense strand includes the sequences shown in SEQ ID NO: 24 and SEQ ID NO: 25, and the antisense strand includes the sequences shown in SEQ ID NO: 34 and SEQ ID NO: 35.
  • Another aspect of the present invention provides a DNA encoding shRNA that inhibits SARS-CoV-2 virus replication, wherein the shRNA targets one of the E, M, and N genes of the SARS-CoV-2 virus, and the DNA comprises Any set of sequences selected from the following combinations:
  • the sense strand is the sequence shown in SEQ ID NO: 36, and the antisense strand is the sequence shown in SEQ ID NO: 41;
  • the sense strand is the sequence shown in SEQ ID NO: 37, and the antisense strand is the sequence shown in SEQ ID NO: 42;
  • the sense strand is the sequence shown in SEQ ID NO: 38, and the antisense strand is the sequence shown in SEQ ID NO: 43;
  • the sense strand is the sequence shown in SEQ ID NO: 39, and the antisense strand is the sequence shown in SEQ ID NO: 44;
  • the sense strand is the sequence shown in SEQ ID NO: 40, and the antisense strand is the sequence shown in SEQ ID NO: 45.
  • Another aspect of the present invention provides a drug for inhibiting SARS-CoV-2 virus replication in a subject, wherein the drug comprises a vector and a nucleic acid sequence encoding a single or multiple shRNA that inhibits SARS-CoV-2 virus replication, wherein The shRNA targets one of the E, M, and N genes of the SARS-CoV-2 virus.
  • the medicament comprises a vector and a shRNA encoding a single shRNA that inhibits SARS-CoV-2 virus replication.
  • the medicament comprises a vector and a plurality of shRNA encoding a plurality of shRNAs that inhibit SARS-CoV-2 virus replication.
  • the nucleic acid sequences encoding multiple shRNAs are located in the same vector. In some embodiments, the nucleic acid sequences encoding multiple shRNAs are located in multiple independent vectors.
  • the vector is a viral vector. In some embodiments, the viral vector is an adeno-associated virus. In some embodiments, the virus is a lentivirus. In some embodiments, the nucleic acid sequence is located in the genome of the viral vector.
  • Another aspect of the present invention provides a method for inhibiting SARS-CoV-2 virus replication in a subject, the method comprising administering to the subject in need an effective amount of the drug of the present invention, wherein the drug comprises a vector and a coded single or Nucleic acid sequences of multiple shRNAs that inhibit SARS-CoV-2 virus replication, wherein the shRNA targets one of the E, M, and N genes of the SARS-CoV-2 virus.
  • the medicament comprises a vector and a shRNA encoding a single shRNA that inhibits SARS-CoV-2 virus replication.
  • the medicament comprises a vector and a plurality of shRNA encoding a plurality of shRNAs that inhibit SARS-CoV-2 virus replication.
  • the nucleic acid sequences encoding multiple shRNAs are located in the same vector. In some embodiments, the nucleic acid sequences encoding multiple shRNAs are located in multiple independent vectors.
  • the vector is a viral vector. In some embodiments, the viral vector is an adeno-associated virus. In some embodiments, the virus is a lentivirus. In some embodiments, the nucleic acid sequence is located in the genome of the viral vector.
  • Another aspect of the present invention provides the application of the medicament of the present invention in the preparation of a medicament for inhibiting the replication of SARS-CoV-2 virus in a subject, wherein the medicament comprises a vector and a code for single or multiple inhibition of SARS-CoV-2 virus
  • the medicament comprises a vector and a shRNA encoding a single shRNA that inhibits SARS-CoV-2 virus replication.
  • the medicament comprises a vector and a plurality of shRNA encoding a plurality of shRNAs that inhibit SARS-CoV-2 virus replication.
  • the nucleic acid sequences encoding multiple shRNAs are located in the same vector. In some embodiments, the nucleic acid sequences encoding multiple shRNAs are located in multiple independent vectors.
  • the vector is a viral vector. In some embodiments, the viral vector is an adeno-associated virus. In some embodiments, the virus is a lentivirus. In some embodiments, the nucleic acid sequence is located in the genome of the viral vector.
  • Another aspect of the present invention provides a pharmaceutical composition for inhibiting SARS-CoV-2 virus replication in a subject, wherein the pharmaceutical composition comprises a vector and encoding single or multiple shRNAs that inhibit SARS-CoV-2 virus replication A nucleic acid sequence drug and a pharmaceutically acceptable excipient, wherein the shRNA targets one of the E, M, and N genes of the SARS-CoV-2 virus.
  • the medicament comprises a vector and a shRNA encoding a single shRNA that inhibits SARS-CoV-2 virus replication.
  • the medicament comprises a vector and a plurality of shRNA encoding a plurality of shRNAs that inhibit SARS-CoV-2 virus replication.
  • the nucleic acid sequences encoding multiple shRNAs are located in the same vector. In some embodiments, the nucleic acid sequences encoding multiple shRNAs are located in multiple independent vectors.
  • the vector is a viral vector. In some embodiments, the viral vector is an adeno-associated virus. In some embodiments, the virus is a lentivirus. In some embodiments, the nucleic acid sequence is located in the genome of the viral vector.
  • Another aspect of the present invention provides a method for inhibiting SARS-CoV-2 virus replication in a subject, the method comprising administering to the subject in need an effective amount of the pharmaceutical composition of the present invention, wherein the pharmaceutical composition contains Vectors, drugs and pharmaceutically acceptable excipients that encode single or multiple shRNA nucleic acid sequences that inhibit SARS-CoV-2 virus replication, wherein the shRNA targets E, M, and N of SARS-CoV-2 virus One of the genes.
  • the medicament comprises a vector and a shRNA encoding a single shRNA that inhibits SARS-CoV-2 virus replication.
  • the medicament comprises a vector and a plurality of shRNA encoding a plurality of shRNAs that inhibit SARS-CoV-2 virus replication.
  • the nucleic acid sequences encoding multiple shRNAs are located in the same vector.
  • the nucleic acid sequences encoding multiple shRNAs are located in multiple independent vectors.
  • the vector is a viral vector.
  • the viral vector is an adeno-associated virus.
  • the virus is a lentivirus.
  • the nucleic acid sequence is located in the genome of the viral vector.
  • Another aspect of the present invention provides the application of the pharmaceutical composition of the present invention in the preparation of a drug for inhibiting SARS-CoV-2 virus replication in a subject, wherein the pharmaceutical composition comprises a carrier containing a single or multiple SARS-inhibiting -Drugs and pharmaceutically acceptable excipients of the nucleic acid sequence of the shRNA replicated by the CoV-2 virus, wherein the shRNA targets one of the E, M, and N genes of the SARS-CoV-2 virus.
  • the medicament comprises a vector and a shRNA encoding a single shRNA that inhibits SARS-CoV-2 virus replication.
  • the medicament comprises a vector and a plurality of shRNA encoding a plurality of shRNAs that inhibit SARS-CoV-2 virus replication.
  • the nucleic acid sequences encoding multiple shRNAs are located in the same vector.
  • the nucleic acid sequences encoding multiple shRNAs are located in multiple independent vectors.
  • the vector is a viral vector.
  • the viral vector is an adeno-associated virus.
  • the virus is a chronic virus.
  • the nucleic acid sequence is located in the genome of the viral vector.
  • Another aspect of the present invention provides a drug set for inhibiting SARS-CoV-2 replication in a subject, the drug set comprising two or more drugs or pharmaceutical compositions of the present invention that exist independently.
  • Figure 1 Transfection efficiency of adeno-associated virus packaged shRNA.
  • the full-field cell scanning analyzer (Celigo) scans and counts the fluorescence intensity of Green fluorescent protein (GFP), SARS-N and DAPI, and calculates the transfection efficiency. Among them, the multiplicity of infection (MOI) is 0.05.
  • Figure 2 The interference effect of adeno-associated virus packaged shRNA.
  • the full-field cell scanning analyzer (Celigo) scans and counts the fluorescence intensity of GFP, SARS-N and DAPI, and calculates the interference efficiency.
  • Figure 3 The interference effect of lentivirus packaged shRNA.
  • the viral nucleoprotein of each group (GFP, shRNA5, shRNA6, shRNA7, shRNA9, shRNA10) was measured by immunofluorescence method, and the interference efficiency was calculated. ***, p ⁇ 0.001, the difference is statistically significant.
  • Figure 4 Immunofluorescence detection of the interference effect of lentivirus packaged shRNA. Use a fluorescence microscope to take pictures.
  • FIG. 5 Virus titer determination.
  • the Focus-forming Assay (FFA) was used to determine the virus titer in cell culture. ****, p ⁇ 0.0001, the difference is statistically significant.
  • FIG. 6 Detection of virus copy number.
  • Enzyme-linked spot analyzer CTL S6 Ultra was used for spot counting.
  • 5 represents the shRNA5 group
  • 6 represents the shRNA6 group
  • 7 represents the shRNA7 group
  • 9 represents the shRNA9 group
  • 10 represents the shRNA10 group.
  • shRNA6N represents the shRNA6 group, where N represents that shRNA6 is a sequence designed for the N protein of the virus
  • shRNA9M represents the shRNA9 group, where M represents that shRNA9 is a sequence designed for the M protein of the virus.
  • FIG. 8 Virus titer in lung tissue of mice after SARS-Cov-2 infection.
  • shRNA-6N represents the shRNA6 group, where N represents that shRNA6 is a sequence designed for the N protein of the virus;
  • shRNA-9M represents the shRNA9 group, where M represents that shRNA9 is a sequence designed for the M protein of the virus. ****, p ⁇ 0.0001, the difference is statistically significant.
  • treatment refers to therapeutic and preventive measures that prevent or slow down the occurrence of undesirable physiological changes or conditions in a subject, such as the occurrence of pulmonary fibrosis or cancer progression.
  • Favorable or desired clinical effects include, but are not limited to, alleviation of symptoms, reduction of disease degree, stabilization of disease state (that is, no deterioration), delay or slowdown of disease progression, reduction or alleviation of disease state, and partial or partial disease All are cured, regardless of whether the above effects are detectable.
  • Treatment can also refer to prolonged survival compared to no treatment.
  • the objects in need of treatment include those who have already suffered from the disease or condition, as well as those who are likely to suffer from the disease or condition, or those who want to prevent the disease or condition.
  • Subject or “patient” or “individual” refers to any subject for which diagnosis, prognosis, or treatment is desired, especially a mammalian subject. Mammals include humans, domestic animals, farm animals, zoo animals, sports animals, or pets, such as dogs, cats, pigs, rabbits, rats, mice, horses, cows, cows, and the like. The object referred to herein is preferably a human.
  • the term "patient in need of treatment” or “subject in need of treatment” includes subjects who benefit from the administration of the polypeptides or compositions thereof for testing, diagnostic and/or therapeutic purposes of the present invention, such as mammalian subjects. .
  • modified genomes as disclosed herein can be modified so that they differ in nucleotide sequence from the modified polynucleotides from which they are derived.
  • a polynucleotide or nucleotide sequence derived from a specified DNA sequence can be similar, for example, it has a certain percentage identity with the starting sequence, for example, it can be 60%, 70%, 75%, or 60% with the starting sequence. 80%, 85%, 90%, 95%, 98%, or 99% are the same.
  • nucleotide or amino acid substitutions, deletions or insertions can be made to make conservative substitutions or changes in "non-essential" regions.
  • a polypeptide or amino acid sequence derived from a specified protein except for one or more individual amino acid substitutions, insertions or deletions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 Except for one or more single amino acid substitutions, insertions or deletions), the rest may be the same as the starting sequence.
  • the polypeptide or amino acid sequence derived from the specified protein has 1 to 5, 1 to 10, 1 to 15, or 1 to 20 individual amino acid substitutions, insertions, or deletions relative to the starting sequence.
  • the term "therapeutically effective amount” or “effective amount” refers to when the drug or pharmaceutical composition of the present invention is administered alone or in combination with another therapeutic agent to a cell, tissue, or subject, it Effectively prevent or slow down the amount of the disease or condition to be treated.
  • a therapeutically effective dose further refers to the amount of the compound sufficient to cause alleviation of symptoms, such as treating, curing, preventing or alleviating related medical conditions, or improving the treatment rate, cure rate, prevention rate, or alleviation rate of the symptoms .
  • the therapeutically effective amount refers to the individual ingredient.
  • the therapeutically effective amount refers to the combined amount of active ingredients that produce a therapeutic effect, regardless of whether it is administered in combination, continuous or simultaneous.
  • a therapeutically effective amount will reduce symptoms usually by at least 10%; usually at least 20%; preferably at least about 30%; more preferably at least 40% and most preferably at least 50%.
  • “about” means that the index value is within the acceptable error range of the specific value determined by a person of ordinary skill in the art, and the value partly depends on how it is measured or determined (that is, the limit of the measurement system). For example, “about” can mean within one or more than one standard deviation in every practice in the art. Alternatively, “about” or “substantially comprising” can mean up to 20% of the range. In addition, for biological systems or processes, the term can mean at most an order of magnitude or at most 5 times the value. Unless otherwise stated, when a specific value appears in this application and claims, the meaning of "about” or “substantially comprising” should be assumed to be within the acceptable error range of the specific value.
  • Coronavirus is a positive-stranded RNA virus, which is currently the virus with the largest genome among RNA viruses known to humans, with a length of 27 to 32 kb. Coronavirus can infect mammals, birds, and reptiles, including humans, pigs, cows, horses, camels, cats, dogs, bats, etc., and cause respiratory, digestive, liver, and nervous system diseases. Coronaviruses belong to the order Nidovirales and Coronaviridae, which can be divided into 4 ( ⁇ , ⁇ , ⁇ , and ⁇ ) coronavirus genera (Coronavirus).
  • coronaviruses known to infect humans, including 2 types of alpha coronaviruses (HCoV-229E and HKU-NL63) and 4 types of beta coronaviruses (HCoV-OC43, HCoV-HKU1, SARS) -CoV and MERS-CoV).
  • HCoV-OC43 and HCoV-HKU1 belong to the A subgroup, which usually cause mild upper respiratory tract infection symptoms, suppress immune activity, and occasionally cause severe lower respiratory tract infections in patients with weakened immunity or the elderly.
  • SARS-CoV of B subgroup and MERS-CoV of C subgroup mainly invade the lower respiratory tract, causing acute respiratory distress syndrome and extrapulmonary clinical symptoms such as diarrhea, lymphopenia, liver dysfunction, and kidney injury.
  • SARS-CoV-2 mainly invades alveolar epithelial cells and causes clinical symptoms similar to SARS-CoV and MERS-CoV infections.
  • the new coronavirus SARS-CoV-2 is an enveloped, unsegmented positive-stranded RNA virus with round or oval particles with a diameter of about 60-140nm and belongs to the ⁇ genus of the Coronavirus family.
  • the genome length is about 30kb.
  • the SARS-CoV-2 genome has a typical coronavirus structure.
  • the genome has a cap-like structure at the 5'end and a poly A tail at the 3'end, which contains two flanking untranslated regions (UTR) and the entire open reading frame (ORF) encoding the polyprotein.
  • the main structural proteins of SARS-CoV-2 include spike (S) protein, envelope (E) protein, membrane (M) protein and nucleocapsid (N) protein. These proteins are essential for the binding of the virus to cell receptors, and are necessary to complete the structure of the virus.
  • E refers to the E gene (Gene ID: 43740570), which encodes (envelope, E) protein.
  • the E protein contains a hydrophobic domain and a transmembrane alpha helix domain, which is a component of the virus envelope and participates in the assembly and release of virus particles.
  • the E protein sequence of SARS-CoV-2 has 95% homology.
  • the E protein of SARS-CoV can also function as an ion channel in the form of a pentameric structure, which also suggests the functional diversity of E protein in the process of SARS-CoV-2 virus replication and pathogenicity.
  • M refers to the M gene (Gene ID: 43740571), which encodes a membrane (M) protein.
  • the M protein contains 3 transmembrane domains and 1 conserved domain. It is a component of the virus envelope and participates in the assembly and release of virus particles.
  • SARS-CoV the M protein sequence of SARS-CoV-2 has up to 91% homology.
  • the M protein of SARS-CoV is only expressed in the endoplasmic reticulum and Golgi apparatus, and its conserved domains participate in the process of virus assembly and budding through protein-protein interactions.
  • S, E, and N proteins there are two conceptual changes in M protein, which play an important role in the structural stability and functional expression of other structural proteins.
  • the envelope of the coronavirus is produced by the endoplasmic reticulum-Golgi intermediate (ERGIC), in which the M protein is responsible for the construction of the envelope skeleton, and the E protein is responsible for the generation of envelope curvature and the mature virus particle package.
  • ERGIC endoplasmic reticulum-Golgi intermediate
  • N refers to the N gene (Gene ID: 43740575), which encodes the nucleocapsid (N) protein.
  • the N protein sequence is highly conserved and plays an important role in the process of virus replication. The main function is to bind to the RNA of the virus. The N protein forms a complex with the viral RNA structure, and then under the joint action of the M protein and the E protein, it enters the virus capsid after being encapsulated.
  • N protein contains N1 and N2 epitopes. Epitope N1 can stimulate the body to produce high-affinity antibodies, but generally has no neutralizing activity. Studies have found that the N protein of ⁇ -coronavirus B subgroup can undergo serum cross-reaction.
  • the N protein homology of SARS-CoV-2 is as high as 90%. Therefore, the serum of SARS-CoV-2 patients may recognize the N protein of SARS-CoV, which can be used for clinical detection of asymptomatic SARS-CoV-2 carriers.
  • RNA interference refers to the phenomenon that double-stranded RNA molecules (dsRNA) enter human cells to specifically degrade the homologous mRNA, thereby specifically and efficiently inhibiting the expression activity of the corresponding gene.
  • dsRNA double-stranded RNA molecules
  • RNA interference was first discovered in plants and lower organisms. With the deepening of research, it has also been discovered in higher eukaryotes recently, and it has proved to be an important evolutionary conservation phenomenon. When a dsRNA homologous to the coding region of an endogenous mRNA is introduced into a cell, the mRNA is degraded to cause gene expression silencing, which is a special type of post-transcriptional gene slience (PTGS).
  • PTGS post-transcriptional gene slience
  • RNAi works by delivering small RNA duplexes, including microRNA (miRNA) mimics, small interfering RNA (siRNA), short hairpin RNA (shRNA) and Dicer substrate RNA (dsiRNA). It has been proved that siRNA is cleaved by dsRNA-specific endonuclease (Dicer enzyme).
  • RISC RNA-induced silencing complex
  • siRNA is composed of siRNA combined with a multi-enzyme complex. It is located in a specific part of mRNA and exerts endonuclease and exonuclease activities to act on mRNA.
  • siRNA has also been shown to reduce protein expression by silencing the promoter by DNA methylation.
  • RNAi Because the use of RNAi has a high degree of sequence specificity and effective interference, it can specifically silence specific genes, thereby obtaining gene function loss or gene expression reduction, so this technology has been widely used to explore gene function, cancer and other diseases. The therapeutic area of antiviral infection.
  • siRNA Small interfering RNA
  • silencing RNA is a type of double-stranded RNA molecule that is 20-25 base pairs in length, similar to miRNA, and operates within the RNA interference (RNAi) pathway. It interferes with post-transcriptionally degraded mRNA of specific genes expressing complementary nucleotide sequences, thereby preventing translation.
  • siRNA is cut into double-stranded RNA (double stranded RNA, dsRNA) by RNase III (such as Dicer) into double-stranded RNA with a size of 21-25bp in the cell.
  • an siRNA that inhibits SARS-CoV-2 virus replication wherein the siRNA targets one of the E, M, and N genes of SARS-CoV-2 virus and has a combination selected from Any pair of sequences in:
  • Table 1 lists SEQ ID NO:1-10.
  • any one of the sequences shown in SEQ ID NO: 1-10 has at least about 70%, or alternatively at least about 75%, or alternatively at least about 80%, or alternatively at least about 85%, or alternatively Polynucleotides having a sequence identity of at least about 90%, or alternatively at least about 95%, or alternatively at least about 97% are considered to be within the scope of the present invention.
  • Short hairpin RNA includes two short inverted repeat sequences.
  • the shRNA cloned into the shRNA expression vector includes two short inverted repeats, separated by a loop sequence in the middle, forming a hairpin structure.
  • shRNA expression is controlled by RNA polymerase (Pol) III promoter or modified pol II promoter. Then connect the transcription terminator. After the shRNA is transcribed, two short inverted repeats connected by a stem loop pair together to form a characteristic hairpin structure.
  • the transcription terminator is 5-6 Ts. In some embodiments, the transcription terminator is 5 T (TTTTT (SEQ ID NO: 46)).
  • the stem loop in the shRNA insert should be close to the center of the oligonucleotide. Stem loops of different sizes and nucleotide sequences have been successfully used. In some embodiments, the sequence of the stem loop is CUCGAG (SEQ ID NO: 47) or CTCGAG (SEQ ID NO: 48).
  • shRNA is usually introduced into cells using vectors and can be passed to progeny cells so that gene silencing can be inherited.
  • the hairpin structure of shRNA can be cleaved into siRNA by the cellular mechanism, and then the mRNA can be degraded according to the aforementioned mechanism. Its biggest advantage is that it has a high degree of effectiveness and specificity, as well as rapid defense and treatment effects.
  • RNAi has an excellent effect on inhibiting the replication of these viruses.
  • a shRNA that inhibits SARS-CoV-2 virus replication wherein the shRNA targets one of the E, M, and N genes of the SARS-CoV-2 virus and includes a combination selected from Any pair of sequences in:
  • a shRNA that inhibits the replication of SARS-CoV-2 virus, wherein the shRNA targets one of the E, M, and N genes of SARS-CoV-2 virus and contains as SEQ ID NO: One of the sequences shown in 11-15. Table 2 lists SEQ ID NO: 11-15.
  • the shRNA targets the N gene and includes the sequence shown in SEQ ID NO: 12. In some embodiments, the shRNA targets the M gene and includes the sequence shown in SEQ ID NO: 14.
  • any one of the sequences shown in SEQ ID NO: 11-15 has at least about 70%, or alternatively at least about 75%, or alternatively at least about 80%, or alternatively at least about 85%, or alternative Polynucleotides having a sequence identity of at least about 90%, or alternatively at least about 95%, or alternatively at least about 97% are considered to be within the scope of the present invention.
  • Deoxyribonucleic acid (English Deoxyribo Nucleic Acid, abbreviated as DNA) is one of the nucleic acids contained in four biological macromolecules in biological cells. DNA carries the genetic information necessary to synthesize RNA and protein. DNA is a macromolecular polymer composed of deoxynucleotides. Deoxynucleotides are composed of bases, deoxyribose and phosphoric acid. There are 4 kinds of bases: adenine (A), guanine (G), thymine (T) and cytosine (C).
  • A adenine
  • G guanine
  • T thymine
  • C cytosine
  • the strand of DNA that carries the nucleotide sequence encoding the amino acid information of the protein is called the sense strand, also known as the coding strand, the sense strand or the positive strand (+ strand).
  • the nucleotide sequence of the other strand is complementary to the sense strand and is called the antisense strand.
  • the strand that has the same nucleotide sequence as the mRNA (U instead of T) is called the sense strand.
  • a single strand of DNA double-strand that can direct transcription to generate RNA according to the rule of base pairing is called the template strand.
  • the term “encoding” refers to any process by which information in a polymer macromolecule or sequence string is used to direct the production of a second molecule or sequence string that is different from the first molecule or sequence string. As used herein, the term is widely used and can have various applications. In one aspect, the term “encoding” describes the process of semi-conservative DNA replication in which one strand of a double-stranded DNA molecule is used as a template to encode a newly synthesized complementary sister strand by a DNA-dependent DNA polymerase. In another aspect, the term “encoding” refers to any process by which information in one molecule is used to direct the production of a second molecule that has a different chemical property from the first molecule.
  • a DNA molecule can encode an RNA molecule (e.g., by participating in the transcription process of a DNA-dependent RNA polymerase).
  • RNA molecules can encode polypeptides, as in the translation process. When used to describe the translation process, the term "encode” also extends to triplet codons that encode amino acids.
  • RNA molecules can encode DNA molecules, for example, by participating in the reverse transcription process of RNA-dependent DNA polymerase.
  • a DNA molecule can encode a polypeptide, where it should be understood that "encoding" as used in this case encompasses both transcription and translation processes.
  • a DNA encoding shRNA that inhibits SARS-CoV-2 virus replication, wherein the shRNA targets one of the E, M, and N genes of the SARS-CoV-2 virus and the DNA contains any set of sequences selected from the following combinations:
  • the sense strand contains the sequence shown in SEQ ID NO: 16 and SEQ ID NO: 17, and the antisense strand contains the sequence shown in SEQ ID NO: 26 and SEQ ID NO: 27;
  • the sense strand includes the sequence shown in SEQ ID NO: 18 and SEQ ID NO: 19, and the antisense strand includes the sequence shown in SEQ ID NO: 28 and SEQ ID NO: 29;
  • the sense strand includes the sequence shown in SEQ ID NO: 20 and SEQ ID NO: 21, and the antisense strand includes the sequence shown in SEQ ID NO: 30 and SEQ ID NO: 31;
  • the sense strand contains the sequence shown in SEQ ID NO: 22 and SEQ ID NO: 23, and the antisense strand contains the sequence shown in SEQ ID NO: 32 and SEQ ID NO: 33;
  • the sense strand includes the sequences shown in SEQ ID NO: 24 and SEQ ID NO: 25, and the antisense strand includes the sequences shown in SEQ ID NO: 34 and SEQ ID NO: 35.
  • a DNA encoding a shRNA that inhibits SARS-CoV-2 virus replication wherein the shRNA targets one of the E, M, and N genes of the SARS-CoV-2 virus and all
  • the DNA contains any set of sequences selected from the following combinations:
  • the sense strand is the sequence shown in SEQ ID NO: 36, and the antisense strand is the sequence shown in SEQ ID NO: 41;
  • the sense strand is the sequence shown in SEQ ID NO: 37, and the antisense strand is the sequence shown in SEQ ID NO: 42;
  • the sense strand is the sequence shown in SEQ ID NO: 38, and the antisense strand is the sequence shown in SEQ ID NO: 43;
  • the sense strand is the sequence shown in SEQ ID NO: 39, and the antisense strand is the sequence shown in SEQ ID NO: 44;
  • the sense strand is the sequence shown in SEQ ID NO: 40, and the antisense strand is the sequence shown in SEQ ID NO: 45.
  • Table 3 lists SEQ ID NO: 16-45.
  • the shRNA targets the N gene and the DNA includes the following sequence: the sense strand is the sequence shown in SEQ ID NO: 37, and the antisense strand is the sequence shown in SEQ ID NO: 42.
  • the shRNA targets the M gene and the DNA includes the following sequence: the sense strand is the sequence shown in SEQ ID NO: 39, and the antisense strand is the sequence shown in SEQ ID NO: 44.
  • any one of the sequences shown in SEQ ID NO: 16-45 has at least about 70%, or alternatively at least about 75%, or alternatively at least about 80%, or alternatively at least about 85%, or alternative Polynucleotides having a sequence identity of at least about 90%, or alternatively at least about 95%, or alternatively at least about 97% are considered to be within the scope of the present invention.
  • Homology refers to the sequence similarity between two peptides or between two nucleic acid molecules. Homology can be determined by comparing the position in each sequence, which can be aligned for comparison purposes. When a position in the compared sequence is occupied by the same base or amino acid, then the molecules are homologous at that position. The degree of homology between sequences is a function of the number of matches or homologous positions shared by the sequences. The "irrelevant” or “non-homologous” sequence shares less than 40% identity with one of the sequences of the invention, but preferably less than 25% identity.
  • a polynucleotide or a polynucleotide region has a certain percentage of another sequence (for example, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% Or 99%)
  • sequence identity means that when the two sequences are compared, the percentage of bases (or amino acids) is the same when comparing two sequences. This alignment and percent homology or sequence identity can be determined using software programs known in the art.
  • polynucleotide and “nucleic acid” as used interchangeably herein refer to a polymerized form of nucleotides (ribonucleotides or deoxyribonucleotides) of any length. These terms include single-stranded, double-stranded or triple-stranded DNA, genomic DNA, cDNA, genomic RNA, mRNA, DNA-RNA hybrids, or polymers; the polymer contains purine or pyrimidine bases, or other natural, chemical, Biochemically modified, non-natural or derived nucleotide bases.
  • the backbone of a polynucleotide may contain sugar and phosphate groups (usually found in RNA or DNA), or modified or substituted sugar or phosphate groups.
  • the backbone of the polynucleotide may contain polymers of synthetic subunits (e.g. phosphoramidates), and therefore may be oligodeoxynucleoside phosphoramidates (P-NH2) or mixed phosphoramidates- Phospholipid diester oligomers.
  • synthetic subunits e.g. phosphoramidates
  • P-NH2 oligodeoxynucleoside phosphoramidates
  • mixed phosphoramidates- Phospholipid diester oligomers oligodeoxynucleoside phosphoramidates
  • a drug for inhibiting SARS-CoV-2 replication in a subject comprising a vector and a nucleic acid sequence encoding single or multiple shRNAs that inhibit SARS-CoV-2 virus replication, wherein The shRNA targets one of the E, M, and N genes of the SARS-CoV-2 virus.
  • the drug comprises a vector and a nucleic acid sequence encoding a single shRNA.
  • the shRNA targets the N gene and includes the sequence shown in SEQ ID NO: 12.
  • the shRNA targets the M gene and includes the sequence shown in SEQ ID NO: 14.
  • the drug comprises a vector and a nucleic acid sequence encoding multiple shRNAs, wherein the shRNA targets one of the E, M, and N genes.
  • the nucleic acid sequences encoding multiple shRNAs are located in the same vector. In some embodiments, the nucleic acid sequence encoding each shRNA is directly connected in tandem or through a linker. In some embodiments, the nucleic acid sequence encoding each shRNA is driven by the same promoter or different promoters. In some embodiments, the multiple shRNAs target the same gene or different genes among the E, M, and N genes.
  • the nucleic acid sequences encoding multiple shRNAs are located in the same vector, the nucleic acid sequences encoding each shRNA are directly connected in tandem and driven by the same promoter, and the multiple shRNAs target E The same gene in, M and N genes. In some embodiments, the nucleic acid sequences encoding multiple shRNAs are located in the same vector, the nucleic acid sequences encoding each shRNA are directly connected in tandem and driven by the same promoter, and the multiple shRNAs target E , M, N genes in different genes.
  • the nucleic acid sequences encoding multiple shRNAs are located in the same vector, the nucleic acid sequences encoding each shRNA are directly connected in tandem and driven by different promoters, and the multiple shRNAs target E The same gene in, M and N genes. In some embodiments, the nucleic acid sequences encoding multiple shRNAs are located in the same vector, the nucleic acid sequences encoding each shRNA are directly connected in tandem and driven by different promoters, and the multiple shRNAs target E , M, N genes in different genes.
  • the nucleic acid sequences encoding multiple shRNAs are located in the same vector, the nucleic acid sequences encoding each shRNA are connected by a linker and driven by the same promoter, and the multiple shRNAs target The same gene in E, M, and N genes. In some embodiments, the nucleic acid sequences encoding multiple shRNAs are located in the same vector, the nucleic acid sequences encoding each shRNA are connected by a linker and driven by the same promoter, and the multiple shRNAs target Different genes in E, M, and N genes.
  • the nucleic acid sequences encoding multiple shRNAs are located in the same vector, the nucleic acid sequences encoding each shRNA are connected by a linker and driven by different promoters, and the multiple shRNAs target The same gene in E, M, and N genes. In some embodiments, the nucleic acid sequences encoding multiple shRNAs are located in the same vector, the nucleic acid sequences encoding each shRNA are connected by a linker and driven by different promoters, and the multiple shRNAs target Different genes in E, M, and N genes.
  • the nucleic acid sequences encoding multiple shRNAs are located in multiple independent vectors.
  • the multiple shRNAs target different genes among the E, M, and N genes.
  • the multiple independent vectors are the same vector.
  • linker refers to a short nucleotide sequence comprising two or more identical or different nucleotides, wherein the nucleotides are selected from Adenine (Adenine, A ), Guanine (Guanine, G), Cytosine (Cytosine, C), Thymine (T) and Uracil (Uracil, U).
  • Promoter is a DNA sequence that RNA polymerase recognizes, binds and starts transcription. It contains conserved sequences required for RNA polymerase specific binding and transcription initiation. Most of them are located upstream of the transcription initiation point of structural genes. The promoter itself is not Transcription. There are three types of eukaryotic promoters, which are transcribed by RNA polymerases I, II, and III.
  • the RNA polymerase I promoter only controls the transcription of rRNA precursor genes, and the transcription product is cut and processed to generate various mature rRNAs.
  • the RNA polymerase II promoter is designed to control the expression of many genes encoding proteins.
  • the RNA polymerase III promoter is involved in the transcription of some small RNA molecules.
  • the promoter is a modified RNA polymerase II promoter or RNA polymerase III promoter.
  • the RNA polymerase III promoter is selected from the group consisting of U6 promoter, H1 promoter, and tRNA promoter.
  • Viral vectors can bring genetic material into cells. The principle is to use the molecular mechanism of viruses to transmit their genomes into other cells for infection. Viral vectors can also be referred to as vectors, vector virus particles, or vector particles. Examples of viral vectors include, but are not limited to: retrovirus, adenovirus, adeno-associated virus, herpes simplex virus, vaccinia virus, baculovirus, or lentivirus.
  • the retroviral vector can be derived or capable of being derived from any suitable retrovirus.
  • retroviruses include but are not limited to: murine leukemia virus (MLV), human T-cell leukemia virus (HTLV), mouse breast tumor virus (MMTV), Rous sarcoma virus (RSV), Fujinami sarcoma virus (FuSV), Moloney Murine Leukemia Virus (Mo MLV), FBR Murine Osteosarcoma Virus (FBR MSV), Moloney Murine Sarcoma Virus (Mo-MSV), Abelson Murine Leukemia Virus (A-MLV), Avian Myeloma Virus-29 (MC29) And Avian Polycythemia Virus (AEV).
  • MMV murine leukemia virus
  • HTLV human T-cell leukemia virus
  • MMTV mouse breast tumor virus
  • RSV Rous sarcoma virus
  • Fujinami sarcoma virus FuSV
  • Adenoviruses are double-stranded linear DNA viruses that do not replicate through RNA intermediates.
  • Adenovirus is a double-stranded DNA non-enveloped virus that can transduce a wide range of cell types of human and non-human origin in vivo, in vitro and in vitro. These cells include airway epithelial cells, hepatocytes, muscle cells, cardiomyocytes, synovial cells, primary breast epithelial cells, and terminally differentiated cells (e.g., neurons) after mitosis.
  • Adenovirus has been used as a vector for gene therapy and heterologous gene expression.
  • the large (36 kb) genome can accommodate up to 8 kb of foreign inserted DNA and can replicate efficiently in complementary cell lines to produce very high titers of up to 1012 transduction units per milliliter.
  • Adenovirus is therefore one of the best systems for studying gene expression in primary non-replicating cells.
  • the expression of viral genes or foreign genes from the adenoviral genome does not require replicating cells.
  • Adenovirus vectors enter cells through receptor-mediated endocytosis. Once inside the cell, the adenovirus vector rarely integrates into the host chromosome. Instead, they exist as episomes (independent of the host genome) as a linear genome in the host cell nucleus.
  • Adeno-associated virus also known as adeno-associated virus, belongs to the genus of dependent viruses in the Parvoviridae family, and is the simplest type of single-stranded DNA-deficient virus found so far.
  • Recombinant AAV vectors have been successfully used for the transduction of marker genes and genes involved in human diseases in vitro, in vitro and in vivo.
  • Certain AAV vectors have been developed that can effectively bind large payloads (up to 8-9 kb).
  • Herpes simplex virus is an enveloped double-stranded DNA virus that naturally infects neurons. It can accommodate large segments of foreign DNA and has been adopted as a carrier for gene delivery to neurons. The use of HSV during treatment requires attenuating the strains so that they cannot establish a lytic cycle.
  • HSV vector is used for gene therapy in humans, it is preferable to insert the polynucleotide into the essential gene. This is because if the viral vector encounters a wild-type virus, the heterologous gene can be transferred to the wild-type virus by recombination. However, if the recombinant virus is constructed in a way that prevents its replication, this can be achieved by inserting oligonucleotides into viral genes necessary for replication.
  • the viral vector of the present invention may be a vaccinia virus vector, such as MVA or NYVAC.
  • vaccinia vectors include, for example, fowlpox or canarypox (avipox) vectors called ALVAC, and strains derived therefrom, which can infect and express recombinant proteins in human cells but cannot replicate . It should be understood that part of the viral genome can remain intact after the insertion of the recombinant gene. This means that viral vectors can retain the concept of the ability to infect cells and subsequently express additional genes that support their replication and may promote the lysis and death of infected cells.
  • Lentiviruses are part of a larger group of retroviruses. Can be divided into primate and non-primate groups. Examples of primate lentiviruses include, but are not limited to: human immunodeficiency virus (HIV), the pathogen of human autoimmune deficiency syndrome (AIDS), and simian immunodeficiency virus (SIV).
  • the non-primate lentivirus group includes the prototype "lentivirus" visna/maedi virus (VMV), as well as the related goat arthritis-encephalitis virus (CAEV), equine infectious anemia virus (EIAV), and feline immunodeficiency virus ( FIV) and Bovine Immunodeficiency Virus (BIV).
  • “Pharmaceutical composition” refers to a pharmaceutical preparation for humans.
  • the pharmaceutical composition comprises a suitable formulation of the medicament of the present invention and a carrier, stabilizer and/or excipient.
  • One aspect of the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a medicament containing a vector and a nucleic acid sequence encoding at least one shRNA, and a pharmaceutically acceptable excipient, wherein the vector contains or carries the nucleic acid sequence encoding at least one shRNA, Wherein the shRNA targets one of the E, M, and N genes.
  • the drug is mixed with a pharmaceutically acceptable carrier or excipient.
  • a pharmaceutically acceptable carrier or excipient for example, lyophilized powder, slurry, aqueous solution or suspension
  • the preparation of therapeutic and diagnostic drugs in the form of, for example, lyophilized powder, slurry, aqueous solution or suspension can be prepared by mixing with physiologically acceptable carriers, excipients or stabilizers.
  • compositions are well known in the art.
  • pharmaceutically acceptable excipients include materials that when combined with the active ingredients of the composition allow the ingredients to maintain biological activity and do not cause a destructive reaction with the subject's immune system. These may include stabilizers, preservatives, salts or sugar complexes or crystals and the like.
  • “Pharmaceutically acceptable” refers to molecules and ingredients that do not produce allergic reactions or similar undesired reactions when administered to the human body. It is known in the art how to prepare an aqueous composition containing as an active ingredient. Generally, these compositions are prepared as injections or sprays, such as liquid solutions or suspensions; they can also be prepared in solid forms suitable for formulating solutions or suspensions before injection or spraying.
  • the medicament or pharmaceutical composition of the present invention can be used alone or in combination with each other.
  • the present invention provides a medicine kit to facilitate the above-mentioned combination therapy, which contains two or more independent drugs or pharmaceutical compositions of the present invention.
  • individuals sometimes administer two or more drugs or pharmaceutical compositions of the present invention at the same time.
  • individuals sometimes administer two or more drugs or pharmaceutical compositions of the present invention separately.
  • One aspect of the present invention provides a method for inhibiting SARS-CoV-2 virus replication in a subject, the method comprising administering an effective amount of the drug of the present invention to the subject in need, wherein the drug comprises a vector and a single or Nucleic acid sequences of multiple shRNAs that inhibit SARS-CoV-2 virus replication, wherein the shRNA targets one of the E, M, and N genes of the SARS-CoV-2 virus.
  • the medicament comprises a vector and a shRNA encoding a single shRNA that inhibits SARS-CoV-2 virus replication.
  • the medicament comprises a vector and a plurality of shRNA encoding a plurality of shRNAs that inhibit SARS-CoV-2 virus replication.
  • the nucleic acid sequences encoding multiple shRNAs are located in the same vector. In some embodiments, the nucleic acid sequences encoding multiple shRNAs are located in multiple independent vectors.
  • the vector is a viral vector. In some embodiments, the viral vector is an adeno-associated virus. In some embodiments, the virus is a lentivirus. In some embodiments, the nucleic acid sequence is located in the genome of the viral vector.
  • the present invention provides the application of the drug of the present invention in a method for inhibiting SARS-CoV-2 virus replication, wherein the drug comprises a vector and a nucleic acid encoding a single or multiple shRNA that inhibits SARS-CoV-2 virus replication Sequence, wherein the shRNA targets one of the E, M, and N genes of the SARS-CoV-2 virus.
  • the medicament comprises a vector and a shRNA encoding a single shRNA that inhibits SARS-CoV-2 virus replication.
  • the medicament comprises a vector and a plurality of shRNA encoding a plurality of shRNAs that inhibit SARS-CoV-2 virus replication.
  • the nucleic acid sequences encoding multiple shRNAs are located in the same vector. In some embodiments, the nucleic acid sequences encoding multiple shRNAs are located in multiple independent vectors.
  • the vector is a viral vector. In some embodiments, the viral vector is an adeno-associated virus. In some embodiments, the virus is a lentivirus. In some embodiments, the nucleic acid sequence is located in the genome of the viral vector.
  • Another aspect of the present invention provides a method for inhibiting SARS-CoV-2 virus replication in a subject, the method comprising administering to the subject in need an effective amount of the pharmaceutical composition of the present invention, wherein the pharmaceutical composition comprises A drug containing a vector, a nucleic acid sequence encoding a single or multiple shRNA that inhibits SARS-CoV-2 virus replication, and a pharmaceutically acceptable excipient, wherein the shRNA targets E, M, and M of the SARS-CoV-2 virus One of the N genes.
  • the medicament comprises a vector and a shRNA encoding a single shRNA that inhibits SARS-CoV-2 virus replication.
  • the medicament comprises a vector and a plurality of shRNA encoding a plurality of shRNAs that inhibit SARS-CoV-2 virus replication.
  • the nucleic acid sequences encoding multiple shRNAs are located in the same vector.
  • the nucleic acid sequences encoding multiple shRNAs are located in multiple independent vectors.
  • the vector is a viral vector.
  • the viral vector is an adeno-associated virus.
  • the virus is a lentivirus.
  • the nucleic acid sequence is located in the genome of the viral vector.
  • the present invention provides the use of the pharmaceutical composition of the present invention in a method for inhibiting SARS-CoV-2 virus replication
  • the pharmaceutical composition comprises a vector containing a vector and encoding single or multiple SARS-CoV-2 viruses Drugs and pharmaceutically acceptable excipients that replicate the nucleic acid sequence of shRNA, wherein the shRNA targets one of the E, M, and N genes of the SARS-CoV-2 virus.
  • the medicament comprises a vector and a shRNA encoding a single shRNA that inhibits SARS-CoV-2 virus replication.
  • the medicament comprises a vector and a plurality of shRNA encoding a plurality of shRNAs that inhibit SARS-CoV-2 virus replication.
  • the nucleic acid sequences encoding multiple shRNAs are located in the same vector. In some embodiments, the nucleic acid sequences encoding multiple shRNAs are located in multiple independent vectors.
  • the vector is a viral vector. In some embodiments, the viral vector is an adeno-associated virus. In some embodiments, the virus is a lentivirus. In some embodiments, the nucleic acid sequence is located in the genome of the viral vector.
  • Suitable routes of administration include parenteral administration (for example, intramuscular, intravenous or subcutaneous administration) and oral administration.
  • the drugs or pharmaceutical compositions of the method of the present invention can be administered in a variety of conventional ways, such as transtracheal intubation, oral ingestion, inhalation, topical application, or transdermal, subcutaneous, intraperitoneal, parenteral, and intraarterial administration. Or intravenous injection.
  • the medicament of the present invention is formulated as a spray formulation.
  • the drug is formulated as a nasal spray formulation.
  • the appropriate dose is determined by the clinician, for example, using parameters or factors known or suspected to affect the treatment or expected to affect the treatment in the art. Usually, the starting dose is slightly lower than the optimal dose, and thereafter a small increase until the desired or optimal effect is achieved relative to any adverse side effects.
  • Important diagnostic measures include measuring, for example, inflammatory symptoms or the level of inflammatory cytokines produced.
  • the medicament or pharmaceutical composition of the present invention can be administered by continuous administration or by administration at certain intervals (for example, one day, one week, or 1-7 times a week).
  • the dose can be provided by tracheal intubation, intravenous, subcutaneous, intraperitoneal, transdermal, topical, oral, transnasal, transrectal, intramuscular, intracerebral, or intraspine.
  • a preferred dosage regimen is a regimen that includes the maximum dosage or dosing frequency that avoids significant undesirable side effects.
  • the new coronavirus (SARS-CoV-2) strain (GenBank: MT123290) was isolated from a patient's throat swab and stored in the P3 laboratory of Guangzhou Customs Technology Center.
  • Vero E6 cells 96-well cell culture plate, DMEM medium, 2% bovine serum DMEM medium, primary antibody, secondary antibody, etc. Freshly prepared 10% hypochlorous acid solution, 4% paraformaldehyde, 1.6% CMC.
  • DAPI staining DAPI (10 ⁇ g/ml) was diluted 5 times with PBS, 200 ⁇ l/well, room temperature, protected from light, 15min.
  • Figure 1 shows the transfection efficiency of 10 shRNAs. Among them, the transfection efficiency of shRNA2, 3, 8 is higher, and the transfection efficiency of shRNA6, 7, 9, 10 is lower.
  • Figure 2 shows the interference effects of 10 shRNAs. The results show that shRNA6 has a significant interference effect, while shRNA5 and shRNA7 also have a certain interference effect. Although the effects of shRNA9 and shRNA10 are not obvious, it may be because of their low transfection efficiency (23% and 16%, respectively).
  • shRNA5 SEQ ID NO: 11, targeting N protein
  • shRNA6 SEQ ID NO: 12, targeting N protein
  • shRNA7 SEQ ID NO: 13, targeting N protein
  • shRNA9 SEQ ID NO: 14.
  • the packaged lentivirus Vero E6 cells were infected, the puromycin resistance stably transfected cells were screened, of 1.5 * 10 4 cells / well were plated in 96-well plates for 24h adherent, according to infection (MOI) of of SARS-COV-2 was added at a dose of 0.05 (non-lethal dose). Immunofluorescence (same as in Example 1) was used to determine the infection efficiency.
  • VeroE6 cells are seeded on a 96-well flat bottom plate, 2 ⁇ 104 cells/well.
  • shRNA5 6, 7, 9, 10 all have varying degrees of inhibiting SARS-COV-2 replication, and shRNA6 and shRNA9 have the most significant effects.
  • siRNA6 and siRNA9 are connected to the same AAV9 vector as ACE2 to construct AAV9-CMV-ACE2-U6-shRNA6 and AAV9-CMV-ACE2-U6-shRNA6 plasmids.
  • the control group uses irrelevant siRNA sequences (NC -siRNA) Construction of AAV9-CMV-ACE2-U6-shNC-RNA plasmid. The above three plasmids were packaged into AAV.
  • mice infected with AAV and SARS-Cov-2 6-week-old female BALB/c mice were anesthetized with 1% sodium pentobarbital, then fixed on a foam board, and the laryngoscope was inserted into the mouse In the throat, the glottis is exposed. Insert the lancet with the plastic hose into the glottis carefully, pull out the needle and leave the plastic hose in place, and use the spray needle to give 2*10 11 AAV-shRNA viruses/control viruses.
  • Nasal drip method Take 6-week-old female BALB/c mice and anesthetize with isoflurane. 2*10 11 AAV-shRNA viruses/control viruses were instilled through the nasal cavity. Seventeen days after infection with AAV, the animals were transported to the P3 laboratory and infected with 1.0 ⁇ 10 5 PFU of SARS-Cov-2 by nasal drip.
  • mice Observe the body weight of the mice: before infection and from day 1 to day 10 after infection, the changes in the body weight of the mice were detected.
  • To detect the level of virus replication in animals prepare a homogenate from animal tissues on the 1st and 3rd day after infection with SARS-Cov-2, add 0.9ml DMEM to each well of a 48-well plate, 10 times serial dilution, and remove the culture In the plate, add 200 ⁇ l of diluted virus sample.
  • the culture plate is placed in the protective box, and then placed in the cell culture box for 1 hour. Gently shake every 15 minutes (put the culture plate in a sealable protective box and transport it to the incubator for culture). Remove the inoculum from the culture plate.
  • mice administered shRNA6 only slightly decreased on the first day after being infected with SARS-Cov-2, and then returned to normal and exceeded the initial body weight; mice administered shRNA9 suffered from SARS-Cov-2 infection.
  • the body weight dropped significantly in the first 3 days, and then gradually increased, but did not recover the initial weight; the mice administered with the control (Ctrl) vector dropped extremely significantly in the first 6 days after the SARS-Cov-2 infection, and then gradually increased, but recovered Less than initial weight.
  • the weight of mice in the shRNA6 group of the control group lost the most, followed by the shRNA9 group.
  • the weight of the mice in the shRNA6 group did not change significantly.

Abstract

L'invention concerne un petit ARN interférent et un petit ARN en épingle à cheveux pour inhiber la réplication du virus du SARS-CoV-2, et un ADN codant pour le petit ARN en épingle à cheveux, ainsi qu'un médicament et une composition de médicament comprenant ce petit ARN en épingle à cheveux.
PCT/CN2021/101493 2020-06-23 2021-06-22 Petit arn en épingle à cheveux pour inhiber la réplication du virus sars-cov-2 et application d'un petit arn en épingle à cheveux WO2021259244A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020097768 2020-06-23
CNPCT/CN2020/097768 2020-06-23

Publications (1)

Publication Number Publication Date
WO2021259244A1 true WO2021259244A1 (fr) 2021-12-30

Family

ID=73804134

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/101493 WO2021259244A1 (fr) 2020-06-23 2021-06-22 Petit arn en épingle à cheveux pour inhiber la réplication du virus sars-cov-2 et application d'un petit arn en épingle à cheveux

Country Status (2)

Country Link
CN (1) CN112111489A (fr)
WO (1) WO2021259244A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112111489A (zh) * 2020-06-23 2020-12-22 深圳罗兹曼国际转化医学研究院 抑制SARS-COV-2病毒复制的shRNA及其应用
CN113144194B (zh) * 2021-02-03 2021-12-14 中国人民解放军军事科学院军事医学研究院 一种GP73抑制剂在制备治疗SARS-CoV-2肺炎及其并发症的药物中的应用
JPWO2022230974A1 (fr) * 2021-04-28 2022-11-03

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050004063A1 (en) * 2003-05-19 2005-01-06 Hsiang-Fu Kung Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference
CN111139242A (zh) * 2020-04-03 2020-05-12 苏州吉玛基因股份有限公司 一种小干扰核酸及组合物和应用
CN111139241A (zh) * 2020-04-03 2020-05-12 苏州吉玛基因股份有限公司 抑制新型冠状病毒的小干扰核酸及组合物和应用
CN111172195A (zh) * 2020-02-13 2020-05-19 翁炳焕 一种新冠肺炎基因治疗制品的制备方法
CN112111489A (zh) * 2020-06-23 2020-12-22 深圳罗兹曼国际转化医学研究院 抑制SARS-COV-2病毒复制的shRNA及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111228464A (zh) * 2020-02-28 2020-06-05 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 广谱抗冠状病毒的多肽及其用途
CN111218459B (zh) * 2020-03-18 2020-09-11 中国人民解放军军事科学院军事医学研究院 一种以人复制缺陷腺病毒为载体的重组新型冠状病毒疫苗

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050004063A1 (en) * 2003-05-19 2005-01-06 Hsiang-Fu Kung Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference
CN111172195A (zh) * 2020-02-13 2020-05-19 翁炳焕 一种新冠肺炎基因治疗制品的制备方法
CN111139242A (zh) * 2020-04-03 2020-05-12 苏州吉玛基因股份有限公司 一种小干扰核酸及组合物和应用
CN111139241A (zh) * 2020-04-03 2020-05-12 苏州吉玛基因股份有限公司 抑制新型冠状病毒的小干扰核酸及组合物和应用
CN112111489A (zh) * 2020-06-23 2020-12-22 深圳罗兹曼国际转化医学研究院 抑制SARS-COV-2病毒复制的shRNA及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DONG JINGYU, SONG JIAJING;SUN YAN;LI ZHI: "The Action Mechanism and Treatment Status of Potential Drugs and Therapies for Coronavirus Disease 2019 ", [SHANXI-SHIFAN-DAXUE-XUEBAO / ZIRAN-KEXUE-BAN] SHANXI-SHIFAN-DAXUE-XUEBAO = JOURNAL OF SHAANXI NORMAL UNIVERSITY : JSNU / NATURAL SCIENCE EDITION, SHANXI-SHIFAN-DAXUE <XI'AN>, CHINA, vol. 48, no. 3, 14 April 2020 (2020-04-14), China , pages 7 - 17, XP055882980, ISSN: 1672-4291, DOI: 10.15983/j.cnki.jsnu.2020.03.016 *
GHOSH SANHITA, FIRDOUS SAYEED MOHAMMAD, NATH ANIRBAN: "siRNA could be a potential therapy for COVID-19", EXCLI JOURNAL, LEIBNIZ RESEARCH CENTRE FOR WORKING ENVIRONMENT AND HUMAN FACTORS, GERMANY, 22 April 2020 (2020-04-22), Germany, pages 528 - 531, XP055882984, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214778/pdf/EXCLI-19-528.pdf> DOI: 10.17179/excli2020-1328 *

Also Published As

Publication number Publication date
CN112111489A (zh) 2020-12-22

Similar Documents

Publication Publication Date Title
WO2021259244A1 (fr) Petit arn en épingle à cheveux pour inhiber la réplication du virus sars-cov-2 et application d&#39;un petit arn en épingle à cheveux
US20220145301A1 (en) siRNA/Nanoparticle Formulations for Treatment of Middle-East Respiratory Syndrome Coronaviral Infection
US9089590B2 (en) Polynucleotides for reducing respiratory syncytial virus gene expression
US20210246448A1 (en) COMPOSITION AND METHODS OF RNAi PROPHYLACTICS AND THERAPEUTICS FOR TREATMENT OF SEVERE ACUTE RESPIRATORY INFECTION CAUSED BY 2019 NOVEL CORONAVIRUS (2019-nCoV)
CN101184839A (zh) 用于呼吸道病毒感染的RNAi治疗
WO2007142792A2 (fr) Inhibition puissante du virus de la grippe par un arn interférent court spécifiquement conçu
CA2917584C (fr) Virus a arn oncolytique genetiquement stable, son procede de fabrication et son utilisation
Huang et al. In vivo inhibition of influenza A virus replication by RNA interference targeting the PB2 subunit via intratracheal delivery
JP2023532735A (ja) 組み換えエンテロウイルスおよびその使用
US20100190842A1 (en) Influenza polynucleotides, expression constructs, compositions, and methods of use
WO2021218802A1 (fr) Poxvirus oncolytique recombinant isolé pouvant être régulé et commandé par microarn et son utilisation
Vigne et al. Inhibition of vaccinia virus replication by two small interfering RNAs targeting B1R and G7L genes and their synergistic combination with cidofovir
US20210348167A1 (en) siNA MOLECULES, METHODS OF PRODUCTION AND USES THEREOF
US11781141B2 (en) Influenza-activated constructs and methods of use thereof
CN110337494B (zh) 表达靶向CDK9的RNAi效应子的H-1 PV
CN109419818B (zh) 一种用于治疗肿瘤的埃可病毒
EP1582591A2 (fr) SiARNs et leur utilisation pour inhiber l&#39;expression de rétrovirus porcins endogènes
KR101682083B1 (ko) MELK 발현을 억제하는 신규 MELK shRNA 및 이의 용도
US20240139307A1 (en) Interferon-producing universal sarbecovirus vaccines, and uses thereof
WO2024094050A1 (fr) Vaccins universels contre les sarbécovirus produisant de l&#39;interféron et leurs utilisations
JP2018148865A (ja) ボルナウイルスベクター及びその利用
JP2022094270A (ja) Ｈ５ｎ６組換えインフルエンザウイルス、その製造用組成物、及びそれを含むワクチン組成物
US20100286238A1 (en) Suppression of viruses involved in respiratory infection or disease
Ahmad et al. Recent patents involving virus nucleotide sequences; host defense, RNA silencing and expression vector strategies
Bennett Characterization of extracellular zinc-mediated inhibition of human HRVs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21830165

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21830165

Country of ref document: EP

Kind code of ref document: A1